Shape and Surface Chemistry Dictate Cellular Internalization Pathways of Mesoporous Silica Nanoparticles.

Advances in the field of nanoparticle biomedical applications have made large strides towards achieving targeted deliver­y of therapeutics and imaging agents. However, less is understood on how the shape of a targeted nanoparticle will alter the level of cellular internalization. The research conducted herein demonstrated that by encasing the bare MSNP with a zwitterionic supported lipid bilayer, referred to as a protocell, the aspect ratio of the MSNP was maintained. However, the non-targeted protocell’s conformal coating drastically diminished the ability of the cell’s active sensory system to recognize the protocell. This finding indicates the cell envokes non-specific macropinocytosis in response to interaction with the silanols present on the bare MSNP surface. Thus, the cell\u27s active shape sensory system is controlled by non-covalent electrostatic and hydrogen bonding interactions with the biomolecular mechanosensitive components of the cell membrane. Additionally, we establish a selective, shape enhanced internalization pathway for the targeted rod shaped protocell AR~1.8-2.3 by conjugation of the SLB with the ligand GE 11, which binds to EGF receptors highly over-expressed on A549 cells. Flow cytometry studies of the effects of chemical inhibitors on nanoparticle cell uptake, along with confocal microscopy colocalization, and TEM studies were performed with A549 cells. The outcomes from these studies showed a shift in the shape-stimulated internalization pathway from non-specific macropinocytosis for anionic bare rod-shaped MSNP to a selective, shape-stimulated, predominantly caveolae-dependent pathway with highly preferential uptake of zwitterionic EGFR-targeted rod shaped protocells in comparison to zwitterionic EGFR-targeted spherical shaped protocells

Inhalation of an Ethanol-Based Zileuton Formulation Provides a Reduction of Pulmonary Adenomas in the A/J Mouse Model

Potential efficacy of zileuton, a 5-LOX inhibitor, was evaluated for the reduction of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation. Development of pulmonary adenomas was induced with benzo(a)pyrene. Animals were treated with a zileuton solution (5 mg/mL in 85:15 ethanol/water) either twice weekly or five times a week via nose-only inhalation; The placebo solution (85:15 EtOH/H2O, no active) was also evaluated. Dose delivered was calculated to be 1.2 mg/kg per exposure for each zileuton group. After 20 weeks of treatment, surface tumors were enumerated and histologically assessed. A significant reduction in tumor count was noted for both the twice weekly administration (40%) and the five times a week administration (59%). The data also showed a significant reduction for the group, which received the placebo (approximately 58%). The treatment groups were also found to have an impact on the histological stages of adenoma development